

# DEAL PROFILE PharmaZell Group | Novasep



## PharmaZell Group

Located in Germany, PharmaZell is a market leader in the highly resilient and specialty API market where it has a diversified portfolio of over 70 APIs and enjoys leading industry positions in several products that treat respiratory, inflammatory, and liver diseases.

**Founded:** 1946      **# of Employees:** ~800      **HQ:** Raubling, Germany



## Novasep

Located in France, Novasep provides cost-effective solutions for the sustainable production of molecules for the life sciences industry. Novasep offers a comprehensive range of services including process development, turnkey purification systems and contract manufacturing.

**Founded:** 1995      **# of Employees:** ~1,250      **HQ:** Lyon, France

## VALUES

**\$540.0M<sup>+1</sup>**

**2,000+**

**10**

Expected Combined  
Revenue

Combined Employees

Production / R&D Sites

## BOURNE PARTNERS MARKET RESEARCH

Bourne Partners provides strategic and financial advisory services to clients throughout the business evolution life cycle. In order to provide the highest level of service, we routinely analyze relevant industry trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, OTC, consumer health, and biotechnology sectors.

## OVERVIEW

PharmaZell, a leading supplier of highly resilient and specialty APIs, and Novasep, a major CDMO focused on complex small molecules and ADCs, announced today the closing of their merger which began exclusive negotiations in September 2021. As a result, this deal creates a leading, technology driven CDMO and API manufacturer backed by Bridgepoint Group PLC, a global private assets growth investor with ~\$35 billion in AUM. Dr. Sylke Hassel, former CEO of PharmaZell and CEO of the new Group, said "Today is a very important step on our journey to better support our customers and the patients they serve. This merger is a significant opportunity to further improve our offering, providing a broader set of technologies, a global manufacturing footprint and an end-to-end lifecycle management."

## HIGHLIGHTS

The deal marks another milestone of consolidation in the outsourced pharma manufacturing space and indicates a continued strategy by industry players to expand capabilities and build out vertically-integrated, end-to-end solutions. Combining the two company's complementary service offerings and capabilities results in the creation of a global pharma services company – with a footprint in Europe, the United States, and India – capable of providing industry leading CDMO and API manufacturing services which can support pharmaceutical and biotechnology customers across the entire drug life cycle.